

Live webinar

# Multi-omics Approach for Discovering Anti-folate Drug Resistance Mechanisms in Triple-negative Breast Cancer: Working toward the Goal of Personalized Medicine

## Event Details

**Date:** May 9, 2018


Coinciding with the 2018 LabRoots Genetics & Genomics Virtual Conference

**Location:** Your Desktop

**Time:** 12:00 p.m. EDT (New York)  
9:00 a.m. PDT (San Francisco)  
6:00 p.m. CET (Berlin)



## Join us for an exclusive live webinar event



### Multi-omics Approach for Discovering Anti-folate Drug Resistance Mechanisms in Triple-negative Breast Cancer: Working toward the Goal of Personalized Medicine

Steven S. Gross, Professor of Pharmacology;  
Director, Advanced Training in Pharmacology;  
Director, Metabolomics Lab

Triple-negative breast cancer (TNBC) has poor prognosis with frequent relapses and deaths using current standard of care treatments. Metabolic reprogramming is now recognized as a fundamental driver of cancer and a detailed understanding of the metabolic rewiring that occurs in TNBC will undoubtedly reveal novel target opportunities. Research will be presented that seeks to use a multi-omics discovery strategy to identify metabolic compensatory in TNBC cells to anti-folate agents. *The overarching goal of our studies is to recognize synthetic lethalties that can be targeted for in TNBC.*

## Register today

[www.labroots.com/virtual-event/genetics-genomics-2018](http://www.labroots.com/virtual-event/genetics-genomics-2018)

For Research Use Only. Not for use in diagnostic procedures.  
This information is subject to change without notice.

© Agilent Technologies, Inc. 2018  
Published in the USA, April 17, 2018  
5991-9242EN